申请人:SACURAI Sérgio Luiz
公开号:US20120040988A1
公开(公告)日:2012-02-16
The present invention describes a series of derivatives of 6,7-dihydro-3H-oxazolo[3,4-a]pyrazine-5,8-dione, mixtures thereof, their pharmaceutically acceptable salts, which are inhibitors of PDE-5, possessing vasodilatator properties and relaxing effects. In particular, the derivative (R)-3-(1,3-benzodioxol-5-yl)-1-(1H-indol-3-yl)-7-methyl-6,7-dihydro[1,3]oxazolo[3,4-a]pyrazine-5,8-dione, its enantiomer (S)-3-(1,3-benzodioxol-5-yl)-
1
-(1H-indol-3-yl)-7-methyl-6,7-dihydro[1,3]oxazolo[3,4-a]pyrazine-5,8-dione.
The present invention describes, additionally, processes for the preparation of said compounds, pharmaceutical compositions containing them, thereof, as well as uses as inhibitors of the enzyme phosphodiesterase type 5 (PDE-5) in the treatment of the erectile dysfunction and PDE-5 inhibitor treatable disorders.
本发明描述了6,7-二氢-3H-噁唑并[3,4-a]吡嗪-5,8-二酮的一系列衍生物、它们的混合物和药学上可接受的盐,这些化合物是PDE-5抑制剂,具有扩血管和放松作用。特别地,本发明描述了(R)-3-(1,3-苯并二氧杂环[5,6-c]戊-1-基)-1-(1H-吲哚-3-基)-7-甲基-6,7-二氢[1,3]噁唑并[3,4-a]吡嗪-5,8-二酮及其对映体(S)-3-(1,3-苯并二氧杂环[5,6-c]戊-1-基)-1-(1H-吲哚-3-基)-7-甲基-6,7-二氢[1,3]噁唑并[3,4-a]吡嗪-5,8-二酮。此外,本发明还描述了制备这些化合物的过程、包含这些化合物的制药组合物以及它们作为磷酸二酯酶5型(PDE-5)的抑制剂在治疗勃起功能障碍和可治疗的PDE-5抑制剂相关疾病中的用途。